Pfizer-BioNTech COVID-19 vaccine's efficacy is significantly reduced against a variant first identified in South Africa but still produces enough antibodies to neutralize the virus. That's the finding of a laboratory study conducted by researchers at the pharmaceutical companies and the University of Texas Medical Branch that engineered versions of the virus to mimic the 501Y.V2 variant.
For more news, visit sabcnews.com and also #SABCNews #Coronavirus #COVID19News on Social Media.
